Category Archives: MS Treatment

4 May 2012 Last updated at 12:40 ET Ukraine's jailed opposition leader Yulia Tymoshenko has agreed to be treated locally for a back problem, according to a visiting German doctor. She had hoped to go abroad, but Ukraine's chief prosecutor has said prison inmates are not allowed to travel for medical treatment. Ms Tymoshenko is serving a seven-year sentence for abuse of office. Several EU leaders have threatened to boycott Euro 2012 football games in Ukraine over how she is being treated. Leaders in the Netherlands and Germany - two of the tournament favourites - have said they will boycott matches in Ukraine, which is co-hosting the games with Poland, if Ms Tymoshenko's treatment does not improve. She is suffering from a herniated disc in her back and her supporters have said she is too ill to remain in jail in Ukraine. The former prime minister was visited on Friday by German physician Dr Karl Max Einhaupl, who told reporters that the authorities had agreed to her request to be treated by a German doctor. Both the German and Russian governments had offered to treat her in their hospitals, but Ukraine has refused to let her leave the country. Dr … Continue reading →

Fourteen years after the Wellsville Multiple Sclerosis (MS) Walk started, there is a greater awareness of the disease which is now said to affect infants and young children. Marlee Cannon, who grew up in Whitesville, but who lives in Wellsville, started the local MS Walk after she was diagnosed with the neurological disease in the 1990s. An active mother with two basketball-minded sons, she said, I wanted to raise awareness and let people know what was happening to me and what may be happening to them. In 1999, when Cannon started the MS Walk, research indicated that MS was a disease which affected the brain and spinal cord, resulting in loss of muscle control, vision, balance and sensation. This usually occurred in women after their mid-30s. But recent research has shown that MS has begun to be diagnosed in infants and toddlers. I have a friend whose 5-year-old granddaughter was diagnosed with MS. They noticed a change in her gait and had her tested, Cannon said. Cannon and Diane Winans, who took over the walk in 2006 and who also has MS, said, Everyone is different, in the way the disease manifests itself. Cannon noticed a problem with sight and … Continue reading →

The Forgan Smith building at the UQ St Lucia campus is lit up red in support of MS Awareness Month. UQ today switches on the red floodlights on the northern side of the Forgan Smith Building in the middle of the Great Court, and will leave them on between 6pm and 11pm every night for the duration of MS Awareness Month, to help raise awareness of the disease. Multiple Sclerosis (MS) is the most common chronic neurological condition amongst young Australian adults today -- a disease that attacks a person's brain and spinal cord causing irreparable damage. More than 21,000 Australians are living with it and, while there is no known cure, researchers at the Queensland Brain Institute (QBI) and the UQ Centre for Clinical Research (UQCCR) are working to find treatments and learn more. Dr Judith Greer, an expert in MS at UQCCR, said the centre was working on understanding more about several aspects of MS. This includes studying genes that appear to be related to development of chronic progressive MS, trying to understand why pregnancy has both short and long-term beneficial effects for women with MS and looking at the role of EBV (the virus that causes glandular … Continue reading →

Select a Publication: N E W S P A P E R S ---------------------------------------------- ---Alberta--- Airdrie - Airdrie Echo Banff - Banff Crag and Canyon Beaumont - Beaumont News Calgary - The Calgary Sun Camrose - Camrose Canadian Canmore - Canmore Leader Central Alberta - County Market Cochrane - Cochrane Times Cold Lake - Cold Lake Sun Crowsnest Pass - Crowsnest Pass Promoter Devon - Dispatch News Drayton - Drayton Valley Western Review Edmonton - Edmonton Examiner Edmonton - The Edmonton Sun Edson - Edson Leader Fairview - Fairview Post Fort McMurray - Fort McMurray Today Fort Saskatchewan - Fort Saskatchewan Record Grande Prairie - Daily Herald Tribune Hanna - Hanna Herald High River - High River Times Hinton - Hinton Parklander Lacombe - Lacombe Globe Leduc - Leduc Representative Lloydminster - Meridian Booster Mayerthorpe - Mayerthorpe Freelancer Nanton - Nanton News Peace Country - Peace Country Sun Peace River - Peace River Record Gazette Pincher Creek - Pincher Creek Echo Sherwood Park - Sherwood Park News Spruce Grove - Spruce Grove Examiner Stony Plain - Stony Plain Reporter Strathmore - Strathmore Standard Vermilion - Vermilion Standard Vulcan - Vulcan Advocate Wetaskiwin - Wetaskiwin Times Whitecourt - Whitecourt Star ---Manitoba--- … Continue reading →

The Elk Grove MS Group will be hosting the number one authority in Multiple Sclerosis (MS) research in northern California, Dr. John Schaefer. He is a neurologist and the director of the Mercy Multiple Sclerosis Center in Carmichael. He earned his MD from the University of Chicagos Pritzker School of Medicine His neurology residency was conducted at the University of California at San Francisco. In addition, Schaefer is the Assistant Clinical Professor of Neurology at the University of California, Davis. He has written extensively on the topics of new treatments for MS, formulary decisions, patient adherence, and the costs of treatment for MS.Schaefer volunteers and serves the MS community at the Northern CA Chapter of the National MS Society. He is on the Professional Advisory Committee and is chair ofthe Central Valley location. He is also on the Chapter Board of Trustees. Joining Dr. Schaefer will be Edie Happs, a Certified Multiple Sclerosis Nurse and a certified rehabilitation nurse. She has focused her interest in Neuro- rehabilitation for the past10 years.She is now the MS nurse at Mercy MS Center in Carmichael. Sheis working withDr. Schaefer and Dr. KarstenDengel. They will present the North American Education Program, Working for Me … Continue reading →

Rachelle Reagan was diagnosed four years ago with multiple sclerosis, which destroys myelin, a protective sheath that surrounds neurons. There is no cure for the auto-immune disease which is marked by flare-ups that have a cumulative, damaging effect on the body. Reagan, 35, of Herrin, Ill., has had three flare-ups. So she was excited to recently learn that her physician, Dr. Florian Thomas, professor of neurology and psychiatry at St. Louis University School of Medicine, will be taking part in studying a new drug, Teriflunomide. It reduced the number of new brain lesions in people with MS in earlier studies, and as a bonus, it comes in pill form. Most existing treatments require injections or infusions. The hope is that Teriflunomide will also reduce the frequency of flare-ups. Each year, about 10,000 people nationwide are diagnosed with multiple sclerosis. About 400,000 are living with the disease today. Reagan's left eye went blind during one flare-up when her immune system attacked the myelin surrounding her optic nerve cells. She estimates that 90 percent of her sight came back, but her vision is not as good as before. She still has problems controlling her legs since another flare-up attacked the myelin surrounding … Continue reading →

Low Dose Naltrexone (LDN) was not originally intended to be a cancer treatment but one local couple encourages everyone with cancer to do their research on this drug. Bonnie and Ken Shockey both use LDN, but for very different reasons. Bonnie takes the drug to treat multiple sclerosis (MS), but Ken began taking it when he was diagnosed with prostate cancer. Both Ken and Bonnie have had positive results with the drug and hope one day it will be added to the list of options for treating different cancers. In laboratory studies, LDN stopped the growth of new cancer cells, but did not kill the cancer. Started with MS Bonnie was diagnosed with MS in 2007 and was on a traditional Federal Food and Drug Adminstration approved treatment, until having a severe allergic reaction to the protein in the drug. Shockey started researching at her neurologists suggestion and came across LDN as a possible treatment for MS. She started taking LDN in April of 2009, seeing results after just five days. It literally reversed some of the MS symptoms I had had for several decades, she said. Kens diagnosis In 2010, Ken was diagnosed with an aggressive, advanced form of … Continue reading →

22-04-2012 22:54 Go here to read the rest: Multiple Sclerosis: Symptoms and Treatment - Video … Continue reading →

Editor's Choice Main Category: Multiple Sclerosis Article Date: 24 Apr 2012 - 0:00 PDT email to a friend printer friendly opinions Current Article Ratings: 1 (1 votes) Gilenya (fingolimod) is the only oral therapy approved to treat relapsing forms of multiple sclerosis (MS)1,2. It is the first in a new class of sphingosine 1-phosphate receptor (S1PR) modulating compounds and has demonstrated superior efficacy over Avonex (interferon-beta-1a IM), a commonly prescribed treatment. In a pivotal head-to-head trial in patients with relapsing- remitting multiple sclerosis at one year, Gilenya achieved both its primary and secondary endpoints, i.e. a 52% relative reduction of the yearly relapse rate and a 40% relative reduction in the rate of brain atrophy. A recent sub-analysis at one year revealed that in comparison to interferon-beta-1a (IM), Gilenya achieved a 61% relative reduction in the rate of yearly relapses in patient subgroups with highly active relapsing-remitting MS patients who previously received interferon therapy. Gilenya has no label restrictions specific to treatment duration and was generally well tolerated during clinical trials with a manageable safety profile. Since February 2012, over 36,000 patients have been treated with Gilenya in clinical trials and in the post-marketing setting, which confirms Gilenya's long- term … Continue reading →

Editor's Choice Main Category: Multiple Sclerosis Also Included In: Regulatory Affairs / Drug Approvals Article Date: 23 Apr 2012 - 11:00 PDT email to a friend printer friendly opinions Current Article Ratings: 1 (1 votes) In agreement with the CHMP, the company has updated their E.U. product information after the Article 20 review the EMA announced in January 2012, in order to offer further guidance to healthcare providers who want to initiate using Gilenya in MS patients. In the E.U., Gilenya is approved for the treatment of individuals with highly active relapsing-remitting MS, regardless of treatment with beta interferon, or in patients with rapidly evolving severe relapsing-remitting MS. Gilenya is the first in a new class of sphingosine 1-phosphate receptor (S1PR) modulating compounds and has demonstrated superior efficacy over Avonex (interferon-beta-1a IM), a commonly prescribed treatment. In a pivotal head-to-head trial in patients with relapsing- remitting multiple sclerosis at one year, Gilenya achieved both its primary and secondary endpoints, i.e. a 52% relative reduction of the yearly relapse rate and a 40% relative reduction in the rate of brain atrophy. A recent sub-analysis at one year revealed that in comparison to interferon-beta-1a (IM), Gilenya achieved a 61% relative reduction in … Continue reading →